ERBB2 and invasive breast carcinoma: The absence of a known ligand for ERBB2 has been the major difficulty to address how the receptor functions in ERBB2-overexpressing BrCa cells, and indeed most studies have relied on the stimulation of the partner receptor in ERBB2-containing heterodimers.